OBJECTIVE: Some antiretroviral treated HIV-infected patients develop Kaposi's sarcoma despite long-term suppression of HIV replication. These Kaposi's sarcoma lesions are consistent with Kaposi's sarcoma observed in the elderly uninfected population ('classical Kaposi's sarcoma'). We investigated potential mechanisms for this phenomenon, focusing on measures of immune activation and T-cell senescence. DESIGN: We compared markers of immunosenescence, naive T cells, activation, and inflammation in CD4+ and CD8+ T cells from antiretroviral-treated participants with new-onset Kaposi's sarcoma (cases, n = 19) and from treated individuals without Kaposi's sarcoma (controls, n = 47). RESULTS: There was increased frequency of CD4+ and CD8+ T cells with an immunosenescence phenotype (CD57+ and CD28-) in cases vs. controls (CD4+ T cells: CD57+ 7.4 vs. 3.7%, P = 0.025; CD28- 9.1 vs. 4.8%, P = 0.025; CD8+ T cells: CD57+ 41.5 vs. 27.7%, P = 0.003; CD28- 60.5 vs. 51.3%, P = 0.041). Cases had lower proportions of naïve T cells (CD27+ CD28+ CD45RA+) in CD4+ (23.0 vs. 32.2%, P = 0.023) and CD8+ (11.3 vs. 20.7%, P < 0.001) T-cell compartments. CCR5 was more highly expressed in CD4+ (16.3 vs. 11.0%, P = 0.025), and CD8+ (43.1 vs. 28.3%, P < 0.001) T-cell compartments in cases vs. controls. There was no difference in telomere length or telomerase activity in peripheral blood mononuclear cells, or in T-cell expression of activation markers (HLADRCD38). CONCLUSION: Among antiretroviral-treated patients, increased frequencies of T cells with an immunosenescence phenotype and lower frequencies of naive T cells were associated with presence of Kaposi's sarcoma among effectively treated patients. These data suggest that certain immunologic perturbations--including those associated with aging--might be causally associated with development of Kaposi's sarcoma.
OBJECTIVE: Some antiretroviral treated HIV-infectedpatients develop Kaposi's sarcoma despite long-term suppression of HIV replication. These Kaposi's sarcoma lesions are consistent with Kaposi's sarcoma observed in the elderly uninfected population ('classical Kaposi's sarcoma'). We investigated potential mechanisms for this phenomenon, focusing on measures of immune activation and T-cell senescence. DESIGN: We compared markers of immunosenescence, naive T cells, activation, and inflammation in CD4+ and CD8+ T cells from antiretroviral-treated participants with new-onset Kaposi's sarcoma (cases, n = 19) and from treated individuals without Kaposi's sarcoma (controls, n = 47). RESULTS: There was increased frequency of CD4+ and CD8+ T cells with an immunosenescence phenotype (CD57+ and CD28-) in cases vs. controls (CD4+ T cells: CD57+ 7.4 vs. 3.7%, P = 0.025; CD28- 9.1 vs. 4.8%, P = 0.025; CD8+ T cells: CD57+ 41.5 vs. 27.7%, P = 0.003; CD28- 60.5 vs. 51.3%, P = 0.041). Cases had lower proportions of naïve T cells (CD27+ CD28+ CD45RA+) in CD4+ (23.0 vs. 32.2%, P = 0.023) and CD8+ (11.3 vs. 20.7%, P < 0.001) T-cell compartments. CCR5 was more highly expressed in CD4+ (16.3 vs. 11.0%, P = 0.025), and CD8+ (43.1 vs. 28.3%, P < 0.001) T-cell compartments in cases vs. controls. There was no difference in telomere length or telomerase activity in peripheral blood mononuclear cells, or in T-cell expression of activation markers (HLADRCD38). CONCLUSION: Among antiretroviral-treated patients, increased frequencies of T cells with an immunosenescence phenotype and lower frequencies of naive T cells were associated with presence of Kaposi's sarcoma among effectively treated patients. These data suggest that certain immunologic perturbations--including those associated with aging--might be causally associated with development of Kaposi's sarcoma.
Authors: Sheila C Dollard; Kenrad E Nelson; Paul M Ness; Veronica Stambolis; Matthew J Kuehnert; Philip E Pellett; Michael J Cannon Journal: Transfusion Date: 2005-04 Impact factor: 3.157
Authors: Brinda Emu; Elizabeth Sinclair; David Favre; Walter J Moretto; Priscilla Hsue; Rebecca Hoh; Jeffrey N Martin; Douglas F Nixon; Joseph M McCune; Steven G Deeks Journal: J Virol Date: 2005-11 Impact factor: 5.103
Authors: J P Pommier; L Gauthier; J Livartowski; P Galanaud; F Boué; A Dulioust; D Marcé; C Ducray; L Sabatier; J Lebeau; F D Boussin Journal: Virology Date: 1997-04-28 Impact factor: 3.616
Authors: Diego Serraino; Angela De Paoli; Antonella Zucchetto; Simona Pennazza; Silvia Bruzzone; Michele Spina; Paolo De Paoli; Giovanni Rezza; Luigino Dal Maso; Barbara Suligoi Journal: Cancer Epidemiol Date: 2010-04-22 Impact factor: 2.984
Authors: Angela Meier; J Judy Chang; Ellen S Chan; Richard B Pollard; Harlyn K Sidhu; Smita Kulkarni; Tom Fang Wen; Robert J Lindsay; Liliana Orellana; Donna Mildvan; Suzane Bazner; Hendrik Streeck; Galit Alter; Jeffrey D Lifson; Mary Carrington; Ronald J Bosch; Gregory K Robbins; Marcus Altfeld Journal: Nat Med Date: 2009-07-13 Impact factor: 53.440
Authors: Michael J Cannon; Eva A Operskalski; James W Mosley; Kay Radford; Sheila C Dollard Journal: J Infect Dis Date: 2009-06-01 Impact factor: 5.226
Authors: Jerry Polesel; Silvia Franceschi; Barbara Suligoi; Emanuele Crocetti; Fabio Falcini; Stefano Guzzinati; Marina Vercelli; Roberto Zanetti; Giovanna Tagliabue; Antonio Russo; Stefano Luminari; Fabrizio Stracci; Vincenzo De Lisi; Stefano Ferretti; Lucia Mangone; Mario Budroni; Rosa Maria Limina; Silvano Piffer; Diego Serraino; Francesco Bellù; Adriano Giacomin; Andrea Donato; Anselmo Madeddu; Susanna Vitarelli; Mario Fusco; Roberto Tessandori; Rosario Tumino; Pierluca Piselli; Luigino Dal Maso; Mauro Lise; Antonella Zucchetto; Angela De Paoli; Teresa Intrieri; Rosa Vattiato; Paola Zambon; Antonella Puppo; Silvia Patriarca; Andrea Tittarelli; Mariangela Autelitano; Claudia Cirilli; Francesco La Rosa; Paolo Sgargi; Enza Di Felice; Rosaria Cesaraccio; Francesco Donato; Silva Franchini; Loris Zanier; Fabio Vittadello; Pier Carlo Vercellino; Gennaro Senatore; Maria Lia Contrino; Silvia Antonini; Raffaele Palombino; Sergio Maspero; Maria Guglielmina La Rosa; Laura Camoni; Vincenza Regine Journal: Int J Cancer Date: 2010-09-01 Impact factor: 7.396
Authors: Salvinia Mletzko; David J Pinato; Rebecca C Robey; Alessia Dalla Pria; Peter Benson; Nesrina Imami; Mark Bower Journal: Oncoimmunology Date: 2017-04-07 Impact factor: 8.110
Authors: Dirk P Dittmer; Kristen Tamburro; Huichao Chen; Anthony Lee; Marcia K Sanders; Tischan A Wade; Sonia Napravnik; Jennifer Webster-Cyriaque; Mahmoud Ghannoum; Caroline H Shiboski; Judith A Aberg Journal: AIDS Date: 2017-09-24 Impact factor: 4.177
Authors: Elizabeth L Yanik; Chad J Achenbach; Satish Gopal; Anna E Coghill; Stephen R Cole; Joseph J Eron; Richard D Moore; W Christopher Mathews; Daniel R Drozd; Ayad Hamdan; Mary E Ballestas; Eric A Engels Journal: J Clin Oncol Date: 2016-08-09 Impact factor: 44.544